Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities



Status:Recruiting
Conditions:Women's Studies, Endocrine
Therapuetic Areas:Endocrinology, Reproductive
Healthy:No
Age Range:2 - 17
Updated:5/5/2018
Start Date:July 2012
End Date:March 2019
Contact:Jane C Burns, MD
Email:jcburns@ucsd.edu
Phone:858-246-0155

Use our guide to learn which trials are right for you!

Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the
developed world. Despite available treatment, 25% of children in San Diego County
appropriately treated for KD develop coronary artery abnormalities that could lead to
complications later in life, including heart attack. Although investigators can identify
children with KD that have these coronary artery abnormalities, there is no approved
additional treatment to decrease coronary artery inflammation and arrest or prevent damage to
the coronary arteries. Inflammation and damage to the arterial wall is central to these
coronary artery abnormalities. Statins, a class of drugs that is known for lowering
cholesterol, have also been shown to decrease inflammation in general as well as at the level
of the vessel wall. Therefore, the investigators propose to study the safety of the drug
atorvastatin in children with coronary artery abnormalities from KD.


Inclusion criteria:

1. Age ≥ 2 years to 17 years old

2. Meets clinical criteria for KD according to American Heart Association guidelines
(Table 2): Fever (T≥38oC or 100.4oC) ≥ 3 days and ≥ 2 clinical criteria with left
anterior descending coronary artery/right coronary artery z-score ≥ 2.5 or an aneurysm
(≥ 1.5 x the adjacent segment) of one of the coronary arteries

3. Patient presents within the first 20 days after fever onset

4. Parent or legal guardian able and willing to provide informed consent and subject
willing and able to provide assent when appropriate.

5. Post-menarchal females: Negative pregnancy test at screening and willing to use two
forms of contraception during the study

6. Males engaging in sexual activity that could lead to pregnancy must use a condom.

Exclusion Criteria:

1. Use of a statin, fibrate, or niacin within the 3 months prior to enrollment

2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled
seizure disorder

3. Screening creatine phosphokinase (CK) ≥ 3x upper limit of normal for age

4. Patient taking a CYP3A4 inhibitor (ie. cyclosporine or clarithromycin) in the last 7
days

5. Patient has a history of allergy to atorvastatin or its derivatives
We found this trial at
1
site
San Diego, California 92093
Principal Investigator: Jane C Burns, MD
Phone: 858-246-0012
?
mi
from
San Diego, CA
Click here to add this to my saved trials